Q-omics provides the consensus-scored ZNF788P profile across patient tissues and cancer cell-line models. ZNF788P expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, ZNF788P is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, ZNF788P RNA expression shows 19,497 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, and UVM as cancer lineages where ZNF788P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF788P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF788P survival associations across molecular data types. ZNF788P RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF788P RNA expression–survival associations across cancer types. High ZNF788P expression shows unfavorable associations in KICH, LGG, STAD and LUSC, but favorable associations in KIRC and MESO. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for ZNF788P RNA expression.
This table summarizes ZNF788P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF788P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF788P shows lower tumor expression in KICH, KIRP, COAD, THCA and LUAD and higher tumor expression in LIHC. The KICH box plot shows higher ZNF788P RNA expression in normal versus tumor tissue (log2 FC = −1.181, t-test p < 0.001).
This table shows molecular features associated with ZNF788P in patient tissues and cancer cell lines. In patient samples, ZNF788P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF788P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BREAST.
